WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--The results from a pre-specified upper gastrointestinal safety analysis of the MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-Term) Program comparing the investigational selective COX-2 inhibitor ARCOXIA® (etoricoxib) and diclofenac, the most widely prescribed non-steroidal anti-inflammatory drug (NSAID) in the world, were published in the February 10, 2007 issue of The Lancet.
